Feed PGEN
PG

Precigen, Inc.

PGEN · NASDAQ

$7.87 +2.88% (+$0.22)
1M +10.22%
Market Cap $2.65B
P/E Ratio -
Div. Yield -
ROE 498.32%

Bulios Fair Price

$5.46

30.6% downside

Trenutna cena

$7.87

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica PGEN trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Odkleni pošteno ceno

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
4/9
Valuation
0 /100
Expensive
P/S 30.92x
P/B 60.83x
P/E N/A
Growth
0 /100
Declining
Rev. growth 28.87%
Book val. growth 45.08%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 89.56%
Net margin 183.98%
Op. margin 46.08%
Quality
6 /100
Poor
ROIC 27.82%
ROE 498.32%
ROA 92.61%
Debt
28 /100
High
Debt/Equity 2.26x
Current ratio 4.58x
Int. coverage -15.21x
Stability
22 /100
Unstable
Beta 1.02x
Rev. volatility 119.25%
EPS volatility 110.87%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o PGEN
Online

O podjetju

Precigen, Inc. (PGEN) is a biotechnology company focused on the development and commercialization of advanced therapeutic and diagnostic technologies. The company specializes in genome engineering and genetic manipulation, enabling the development of novel drugs and diagnostic tools for the treatment and detection of various diseases. Their technologies include CRISPR-Cas9 and other genome editing tools, gene therapy, immunotherapy, and genetic analysis-based diagnostic tests.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Helen Sabzevari

Employees

160

Headquarters

Germantown

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

56d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.